AI virtual cell startup Yuanshi raises ~$42M Pre-A, a record for China's AIVC field
智东西 · wechat · 2026-11-20
Shanghai-based AI drug-discovery startup Yuanshi Technology announced a Pre-A round of nearly RMB 300 million ($42M), led by Legend Capital with follow-ons including a JD-affiliated fund, CMC Capital and others — a record single round for China's AI virtual cell (AIVC) space, and its third raise within a month after nearly RMB 100M in angel rounds in October.
- Founded in April 2025, Yuanshi builds AI virtual cell models that predict cellular responses across disease states, experimental conditions and interventions. CTO Dong Mingze, a Yale computational biology PhD and former Anthropic AI safety researcher, recently joined full-time.
- Its approach is a wet-dry closed loop of "model prediction → experimental validation → data feedback → model update," which the company calls applying recursive self-improvement (RSI) to biological foundation models.
- It partnered with Yongsheng Intelligence (a BGI Genomics subsidiary) to build an automated virtual-cell experiment platform.
- Commercial precedent: Roche accepted and is paying for Recursion's microglia atlas, showing pharma pays for cell data.
More from Venture
- Kylon launches AI finance agents that paid $233K in supplier bills over four months — ying11231 · 2026-11-20
- Anthropic IPOs as the first 'Neolab': founded 2021, coding-only focus, zero cofounder departures — Yuchenj_UW · 2026-11-20
- GrayPass (YC F26) hits $66K MRR in two months policing AI agent actions in apps — ycombinator · 2026-11-20
- Anthropic stock ANT opens at $105 then slides, down 4.3% on debut — SumitGup · 2026-11-20
- Anthropic IPO 6-7x Oversubscribed, Small Funds Locked Out Explain AMZN Dip — _onionesque · 2026-11-20
- Wedbush raises Nvidia price target to $293, says leadership risks already priced in — sudoraohacker · 2026-11-20